The Philippines Food and Drug Administration (FDA) has issued FDA Circular No. 2022-005, which provides some information on the process on labelling drug products under Maximum Retail Price (MRP), in June 2022.
The FDA Circular is relevant for all licensed drug manufacturers, traders, and distributors of drug products under MRP, whereby clear instructions have been shared on the printing of MRP statement on the packaging label of the drug product.
The exhaustion period granted for old labelling materials of registered drug products is one year from the effective date of the circular (23 June 2022).
More details can be found in “FDA Circular No.2022-005: Guidelines on Labelling Requirements of Drug Products under Maximum Retail Price (MRP), June 2022”: https://www.fda.gov.ph/wp-content/uploads/2022/06/FDA-Circular-No.-2022-005.pdf